- Home
- Publications
- Publication Search
- Publication Details
Title
Ipragliflozin: First Global Approval
Authors
Keywords
Metformin, Pioglitazone, Sulfonylurea, Sitagliptin, Saxagliptin
Journal
DRUGS
Volume 74, Issue 5, Pages 611-617
Publisher
Springer Nature
Online
2014-03-25
DOI
10.1007/s40265-014-0204-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects
- (2013) Stephan A. Veltkamp et al. CLINICAL DRUG INVESTIGATION
- The Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Ipragliflozin, a Novel Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor
- (2013) Wenhui Zhang et al. CLINICAL DRUG INVESTIGATION
- Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
- (2013) Atsuo Tahara et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors
- (2013) S. Cangoz et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Discovery of Ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus
- (2012) Masakazu Imamura et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Combination Treatment With Ipragliflozin and Metformin: A Randomized, Double-Blind, Placebo-Controlled Study in Patients With Type 2 Diabetes Mellitus
- (2012) Stephan A. Veltkamp et al. CLINICAL THERAPEUTICS
- Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
- (2012) Muhammad A. Abdul-Ghani et al. Current Diabetes Reports
- Loss of Pdk1-Foxo1 Signaling in Myeloid Cells Predisposes to Adipose Tissue Inflammation and Insulin Resistance
- (2012) Y. Kawano et al. DIABETES
- No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects
- (2012) R. A. Smulders et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study
- (2012) J. P. H. Wilding et al. DIABETES OBESITY & METABOLISM
- Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus
- (2012) Vivian A. Fonseca et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Antidiabetic Effects of SGLT2-Selective Inhibitor Ipragliflozin in Streptozotocin^|^ndash;Nicotinamide-Induced Mildly Diabetic Mice
- (2012) Atsuo Tahara et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus
- (2012) Monika Misra JOURNAL OF PHARMACY AND PHARMACOLOGY
- Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus
- (2011) Sherwyn L. Schwartz et al. Diabetes Technology & Therapeutics
- Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo
- (2011) Atsuo Tahara et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started